SCHEMBL24029048

SCHEMBL24029048

O=C(O)c1ccc(-n2nnnc2SCc2ccccc2Br)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 8/20 1.00
▸ MEN1 O00255 7/20 1.00
▸ PPARG P37231 1/20 1.00
▸ ALDH1A1 P00352 7/20 0.76
▸ HPGD P15428 4/20 0.76
▸ MAPK1 P28482 4/20 0.76
▸ ATM Q13315 1/20 0.60
▸ NPSR1 Q6W5P4 2/20 0.58
▸ LMNA P02545 1/20 0.58
▸ GAA P10253 1/20 0.58
▸ TSHR P16473 1/20 0.58
▸ POLB P06746 3/20 0.53
▸ MAPT P10636 1/20 0.53
▸ PKM P14618 1/20 0.50
▸ CRHBP P24387 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ CRHR2 Q13324 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24019575 0.86 ALDH1A1 (1.00) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL24019808 0.86 KMT2A (0.76) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL24019599 0.84 HPGD (1.00) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL24209699 0.78 HPGD (0.79) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL24209682 0.78 MAPT (0.71) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL24019594 0.77 TP53 (0.72) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL21951986 0.76 MAPT (0.71) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL21952082 0.76 MAPT (0.64) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL24019574 0.76 HPGD (0.80) KMT2AMEN1PPARGALDH1A1HPGD
SCHEMBL16268464 0.76 TSHR (0.80) KMT2AMEN1PPARGALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 — — US disclosed
WO-2021229035-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUNDACIÓN PROFESOR NOVOA SANTOS (ES) 2021-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER XIAP, UBQLN1, MDM2 KMT2A 663/4885MEN1 3372/4885PPARG 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback